Service delivery in acute ischemic stroke patients: Does sex matter?

Friedrich Medlin; Davide Strambo; Dimitris Lambrou; Valeria Caso; Patrik Michel

doi:10.1101/2023.06.19.23291634

Abstract

Background Women with acute ischemic stroke (AIS) are older and have higher preexisting handicap than men. Given that these factors do not fully explain their poorer long-term outcomes, we sought to investigate potential sex differences in the delivery of acute stroke care in a large cohort of consecutive AIS patients.

Methodss We analyzed all patients from the Acute STroke Registry and Analysis of Lausanne (ASTRAL) from 03/2003-12/2019. Multivariate analyses were performed on acute time metrics, revascularization therapies, ancillary exams for stroke work-up, subacute symptomatic carotid artery revascularization, frequency of change in goals of care (palliative care) and length of hospital stay.

Results Of the 5347 analyzed patients, 45% were biologically female and the median age was 74.6 years. After multiple adjustments, female sex was significantly associated with higher onset-to-door (adjusted hazard ratio (aHR):1.09, 95% confidence interval (CI) 1.04-1.14) and door-to-endovascular-puncture intervals (aHR:1.15, 95%CI:1.05-1.25). Women underwent less diagnostic exams (adjusted odds ratio (aOR): 0.94, 95%CI:0.85-1.04), fewer subacute carotid revascularizations (aOR:0.69, 95% CI:0.33-1.18) and had longer hospital stays (aHR:1.03, 95%CI:0.99-1.07), but these differences were not statistically significant. We found no differences in the rates of acute revascularization treatments, or in the frequency of change of goals of treatments.

Conclusions In this retrospective analysis of a large, consecutive AIS cohort, female sex was associated with unfavorable pre- and inhospital time metrics, and lesser diagnostic exam and carotid revascularization rates. Such indicators of less effective stroke care delivery may contribute to the poorer long-term functional outcomes in female patients and require further attention.

Competing Interest Statement

V. Caso received speaker fees from Bayer and Boehringer-Ingelheim within the past 3 years P. Michel: research grants from the Swiss Heart Foundation, Swiss National Science Foundation and the Faculty of Biology and Medicine of the University of Lausanne.

Clinical Trial

no trial registration because the presented study is a retrospective study

Funding Statement

No external funding for the presented work was received

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Not Applicable

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Not Applicable

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Not Applicable

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Not Applicable

Data Availability

The raw, anonymized data that support the findings of this study are available from the corresponding author upon reasonable request and after signing a data transfer and use agreement (DTUA). If such data are then used for a publication, the publication methods should be communicated, and internationally recognized authorship rules should be applied.